Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Lancet HIV. 2018 Jun 13;5(9):e498–e505. doi: 10.1016/S2352-3018(18)30097-3

Figure 5.

Figure 5

Percent reduction in cumulative number of new HIV infections with LAI-PrEP among MSM in Atlanta, Georgia (2015–2024) relative to equivalent coverage of daily oral PrEP, with varying maximum efficacy of LAI-PrEP.

The average percent reduction is plotted comparing the number of new HIV infections with LAI-PrEP relative to daily oral PrEP. Whiskers indicate 95% simulation intervals.